EPO and cancer: Although HBSP has shown clinical efficacy in improving neuropathy associated with sarcoidosis, clinical trials for other EPO-derived peptides remain scarce, possibly due to concerns that activation of the EPOR pathway may also contribute to cancer progression (Peng et al., 2020).